Andre Georges Vuilliomenet

Suggest Changes
Learn More
AIMS To assess the effects of an NT-proBNP-guided medical management on 18-month outcomes in patients with heart failure (HF) and preserved LVEF ( HFpEF). METHODS AND RESULTS Patients with HFpEF(More)
BACKGROUND No data are available on the long-term performance of ultrathin strut biodegradable polymer sirolimus-eluting stents (BP-SES). We reported 2-year clinical outcomes of the BIOSCIENCE(More)
BACKGROUND Ultrathin strut biodegradable polymer sirolimus-eluting stents (BP-SES) proved noninferior to durable polymer everolimus-eluting stents (DP-EES) for a composite clinical end point in a(More)
BACKGROUND To investigate clinical outcomes of percutaneous coronary intervention using a sirolimus-eluting stent with bioresorbable polymer, Ultimaster (BP-SES) compared with a permanent polymer(More)
AIMS We sought to assess the performance of drug-eluting stents combining an ultrathin cobalt-chromium platform with a biodegradable polymer across categories of increasing SYNTAX score (SS). (More)
RESULTS A total of 1119 confirmed STEMI patients (51.7%) were admitted during OFF-hours and 1048 (48.3%) patients during ONhours. Baseline characteristics were well balanced between the two groups(More)
AIMS Our aim was to compare the safety and efficacy of a novel, ultrathin strut, biodegradable polymer sirolimus-eluting stent (BP-SES) with a thin strut, durable polymer everolimus-eluting stent(More)
TCT-263 Impact of Diabetes on Clinical Outcomes in Patients Undergoing Unprotected Left Main Percutaneous Coronary Intervention with Drug-Eluting Stents Bo Xu, Jonathan Murphy, Yuejin Yang, Shubin(More)